Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
498 Leser
Artikel bewerten:
(2)

Dr. Aletta Schnitzler Joins TurtleTree as Chief Scientific Officer

Finanznachrichten News

DAVIS, Calif. and SINGAPORE, Dec. 1, 2021 /PRNewswire/ -- Cell-based nutrition company TurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO). With her world-class expertise in cellular bioprocessing, Dr. Schnitzler's appointment marks a significant stride in TurtleTree's journey towards sustainable and efficient cellular food production.

With her world-class expertise in cellular bioprocessing, Dr. Schnitzler's appointment marks a significant stride in TurtleTree's journey towards sustainable and efficient cellular food production.

Prior to joining TurtleTree, Aletta was with MilliporeSigma for over 10 years. Her most recent appointment was as R&D Director of the company's Cultured Meat department. There, Aletta led a scientific and engineering team in creating cutting-edge technologies for the manufacturing of cultured meat. She also simultaneously spearheaded business and product development. Informing this leadership role was her previous experience as MilliporeSigma's Head of Cell Therapy Bioprocessing, in which she engineered cost-effective cell culture media and reagents for use in cellular therapeutic applications.

Aletta received her PhD in Immunology and Neuroscience from the Boston University School of Medicine in 2007. Since then, she has achieved multiple career milestones: Besides having developed a xeno-free cell culture medium for mesenchymal stromal cell (MSC) expansion, she is also an editorial board member of Stem Cells Translational Medicine, an international journal dedicated to stem cell research.

Explaining her transition from biopharmaceuticals to cellular agriculture, Aletta said: "Developing life-saving medicines through therapeutic cell manufacturing technologies was immensely gratifying. With cellular agriculture, the aim to better human health with nutritious and diverse alternative protein sources creates the potential to make a broader impact. Being at TurtleTree grants me a vital opportunity to improve our food system and benefit society on a global scale."

As TurtleTree's CSO, Dr. Schnitzler will communicate TurtleTree's scientific interests to internal and external stakeholders. To strategically execute the company's cellular agriculture innovation plans, Aletta will also work closely with the management and scientific teams to align the company's global R&D efforts. With her breadth of experience and networks within the bioprocessing industry, Aletta is poised to secure top-tier expertise and key partnerships for the development of TurtleTree's cultivated food production technologies.

Sharing her excitement about Aletta's new role at TurtleTree, Fengru Lin, CEO of TurtleTree said: "We're incredibly honored to have Aletta and her expertise in both cellular agriculture and therapeutics with us. We're excited to see her apply her experience to creating innovation cycles that will kickstart our productization."

About TurtleTree

TurtleTree is a biotech company dedicated to producing a new generation of nutrition-one that's better for the planet, better for the animals, and better for people everywhere. Utilizing its proprietary, cell-based technology, the company is creating better-for-you milk ingredients sustainably and affordably, with benefits that extend beyond the dining table and into the heart of humanity.

For more information, please visit TurtleTree's website and follow them on Instagram, Twitter, and LinkedIn.

Contact:

Rita Huang
Communications Lead
+1 530 564-2403
rita@turtletree.com

Photo - https://mma.prnewswire.com/media/1700093/ALETTA_PRESS_RELEASE_V2_03.jpg

© 2021 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.